Celgene files Hatch-Waxman suit against Par Pharmaceutical over generic version of ADHD drug Focalin XR®
Client(s) Celgene Corporation
Jones Day represents Celgene Corporation in a patent infringement action against Par Pharmaceutical brought pursuant to the Hatch-Waxman Act relating to Celgene’s patented drug Focalin XR®.
Celgene Corporation et al. v. Par Pharmaceutical, Inc., Civil Action No. 2-11-cv-03094 (D.N.J.) (Judge Arleo)